Defective ALC1 nucleosome remodeling confers PARPi sensitization and synthetic lethality with HRD
DNA Replication
570
Cellbiologi
612
Poly(ADP-ribose) Polymerase Inhibitors
Article
PARPs
Mice
03 medical and health sciences
poly(ADP)-ribosylation
DNA-(Apurinic or Apyrimidinic Site) Lyase
DNA damage repair
Animals
homologous recombination defieciency
chromatin remodeler
Homologous Recombination
Mice, Knockout
0303 health sciences
DNA Helicases
DNA gycosylases
BRCAs
Cell Biology
Neoplasms, Experimental
Chromatin Assembly and Disassembly
base excsion repair
synthetic lethality
Neoplasm Proteins
Nucleosomes
DNA-Binding Proteins
ALC1
CDU::5 - Ciencias puras y naturales::57 - Ciencias biológicas en general:577 - 577 Bioquímica. Biología molecular. Biofísica
Poly(ADP-ribose) Polymerases
DOI:
10.1016/j.molcel.2020.12.006
Publication Date:
2020-12-17T04:42:58Z
AUTHORS (27)
ABSTRACT
Chromatin is a barrier to efficient DNA repair, as it hinders access and processing of certain DNA lesions. ALC1/CHD1L is a nucleosome-remodeling enzyme that responds to DNA damage, but its precise function in DNA repair remains unknown. Here we report that loss of ALC1 confers sensitivity to PARP inhibitors, methyl-methanesulfonate, and uracil misincorporation, which reflects the need to remodel nucleosomes following base excision by DNA glycosylases but prior to handover to APEX1. Using CRISPR screens, we establish that ALC1 loss is synthetic lethal with homologous recombination deficiency (HRD), which we attribute to chromosome instability caused by unrepaired DNA gaps at replication forks. In the absence of ALC1 or APEX1, incomplete processing of BER intermediates results in post-replicative DNA gaps and a critical dependence on HR for repair. Hence, targeting ALC1 alone or as a PARP inhibitor sensitizer could be employed to augment existing therapeutic strategies for HRD cancers.
SUPPLEMENTAL MATERIAL
Coming soon ....
REFERENCES (53)
CITATIONS (111)
EXTERNAL LINKS
PlumX Metrics
RECOMMENDATIONS
FAIR ASSESSMENT
Coming soon ....
JUPYTER LAB
Coming soon ....